View the PDF

Includes: Join our board, Become a donor, FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMApositive mHSPC, Prostate cancer hijacks amino acid metabolism to signal hormone therapy resistance, New drug combination may help treat advanced prostate cancer, Half of prostate cancer focal therapy use found to fall outside current guideline-supported groups, Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy, Cancer-specific c-Myc mapping reveals overlooked SLK protein as treatment target, and more.